{"id":128460,"date":"2021-10-02T18:23:26","date_gmt":"2021-10-03T01:23:26","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/10\/what-would-an-antiviral-pill-mean-for-the-fight-against-covid-19"},"modified":"2021-10-02T18:23:26","modified_gmt":"2021-10-03T01:23:26","slug":"what-would-an-antiviral-pill-mean-for-the-fight-against-covid-19","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/10\/what-would-an-antiviral-pill-mean-for-the-fight-against-covid-19","title":{"rendered":"What would an antiviral pill mean for the fight against Covid-19?"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/what-would-an-antiviral-pill-mean-for-the-fight-against-covid-192.jpg\"><\/a><\/p>\n<p>Merck and Ridgeback Biotherapeutics announced on Friday early result that indicate their experimental oral antiviral drug molnupiravir might halve the risk of death or hospitalization from Covid-19.<\/p>\n<p>In a news release, the company said 7.3% of 385 patients who received the antiviral were either hospitalized or died from Covid-19, compared with 14.1% of the 377 patients who received a placebo, which does nothing.<\/p>\n<p>Full data from the molnupiravir trial has not yet been released, and this data has not yet been peer-reviewed or published. But Merck says it will seek authorization from the US Food and Drug Administration, and if it\u2019s granted, the drug could be the <a href=\"https:\/\/www.cnn.com\/2021\/09\/27\/health\/covid-treatment-pill-khn-partner\/index.html\" target=\"_blank\">first antiviral treatment available orally to fight Covid-19<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck and Ridgeback Biotherapeutics announced on Friday early result that indicate their experimental oral antiviral drug molnupiravir might halve the risk of death or hospitalization from Covid-19. In a news release, the company said 7.3% of 385 patients who received the antiviral were either hospitalized or died from Covid-19, compared with 14.1% of the 377 [\u2026]<\/p>\n","protected":false},"author":656,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-128460","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/128460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/656"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=128460"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/128460\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=128460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=128460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=128460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}